NCT03227731View on ClinicalTrials.gov

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

540

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions

HIV-1-infection

Interventions

DRUG

Truvada

Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.

Trial Locations (1)

4001

University of KwaZulu-Natal, Durban

All Listed Sponsors

collaborator

Centre for the AIDS Programme of Research in South Africa

NETWORK

collaborator

Medical Research Council, South Africa

OTHER

lead

University of KwaZulu

OTHER

NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women | Biotech Hunter | Biotech Hunter